2024 年全球生技投資成長機會

Growth Opportunities in Global Biotech Investment, 2024

出版日期: 2024年04月09日 | 出版商:

Frost & Sullivan | 英文 55 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

領先生物製藥公司的顛覆性技術和投資組合重組確保了生物技術投資的成長潛力

在這份分析中，Frost & Sullivan 提供了有關生物技術併購和創業投資(VC) 投資的重要見解，確定了生物技術領域的促進因素、挑戰、預測和主要趨勢。該分析還確定了行業參與者可以利用的成長機會。

為了了解 2024 年以後的趨勢前景，本分析評估了 2019 年至 2023 年的策略和金融投資、併購）、創投和私募股權(PE)。 Frost & Sullivan 收集了整個生態系統的總數。然而，僅分析不涉及小分子資產的生物技術/生物製藥交易。本分析的範圍是以2023年為基準年的全球，並包含截至2028年的預測。

該評估不包括債務或未決事項。由於資料基於二手資訊，因此處理的數量和金額可能會有所不同。同樣，生物技術的定義也各不相同。一些資訊來源在公告日期記錄併購交易，資訊來源記錄交易進度的里程碑，還有資訊來源記錄交易結束後的總金額。

生長促進因子
成長抑制因素
生物產業現況-生技藥品管線
生物產業現況-生技藥品產業前景
生技併購投資展望 - 2024 年
生技創投展望 – 2024
2024 年三大預測
大型藥廠重塑投資組合的三大投資策略
新興生物技術公司的趨勢 - 影響摘要
新模式持續推動精準醫療的發展
投資者優先考慮心臟代謝、腫瘤學、中樞神經系統和免疫學

成長動力：生技併購

Bioventure併購趨勢
主要生物製藥公司併購活動
生物技術併購分析：按治療領域
生物技術併購分析：依方式分類
2024年生物製藥主要併購目標

成長動力：Bioventure VC投資

生技企業的融資趨勢
頂級風資金籌措項目
Bioventure投資項目分析：依資金籌措階段
Bioventure投資項目分析：依治療領域
Bioventure投資項目分析：依模式
生物創投專案分析：依臨床開發階段

活躍公司

谷歌創投（美國）
ARCH 創投公司（美國）
RA資本（美國）
SamsaraBio資本（美國）
奧博醫療（美國）
亞歷山大（美國）

成長機會宇宙

成長機會一：收購一家專注於罕見疾病的生物製藥公司
成長機會二：投資以精準醫療平台技術為基礎的生技公司
成長機會3：投資臨床階段的中國生物製藥公司

最佳實踐評估

最佳實踐評估

弗羅斯特雷達

Frost Radar

下一步

成長機會的好處和影響
下一步
下一步
圖表列表
免責聲明

簡介目錄

Product Code: PFGA-52

Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.

To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.

This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.

Transformation in Global Biotech Investment

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Global Biotech Investments

Ecosystem

Market Scope and Segmentation
Definitions

Growth Generator

Growth Drivers
Growth Restraints
The State of the Biotech Industry-Biologics Pipeline
State of the Biotech Industry-Biologics Industry Outlook
Biotech M&A Investment Outlook-2024
Biotech VC Investment Outlook-2024
Top 3 Predictions-2024
Top 3 Big Pharma Investment Strategies for Portfolio Remodeling
Emerging Biotech Companies Top Trends-Impact Summary
New Modalities Driving Precision Medicine Will Remain Attractive
Investors Prioritizing Cardiometabolism, Oncology, CNS, and Immunology

Growth Generator: Biotech M&A

Biotech M&A Trends
Big Biopharma M&A Activity
Biotech M&A Analysis by Therapeutic Segment
Biotech M&A Analysis by Modality
Key Biopharma M&A Targets2024

Growth Generator: Biotech VC Investment

Biotech VC Financing Trend
Top VC Financing Deals
Biotech VC Deal Analysis by Funding Stage
Biotech VC Deal Analysis by Therapeutic Segment
Biotech VC Deal Analysis by Modality
Biotech VC Deal Analysis by Stage of Clinical Development

Companies to Action

Google Ventures (United States)
ARCH Ventures (United States)
RA Capital (United States)
SamsaraBio Capital (United States)
OrbiMed (United States)
Alexandria (United States)

Growth Opportunity Universe

Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies
Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies
Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies